Chaperone-mediated autophagy promotes PCa survival during ARPI through selective proteome remodeling

[1]  L. Lacombe,et al.  Multiple metabolic pathways fuel the truncated tricarboxylic acid cycle of the prostate to sustain constant citrate production and secretion , 2022, Molecular metabolism.

[2]  K. Engeland.  Cell cycle regulation: p53-p21-RB signaling , 2022, Cell Death & Differentiation.

[3]  S. Verma,et al.  Role of solute carrier transporters SLC25A17 and SLC27A6 in acquired resistance to enzalutamide in castration‐resistant prostate cancer , 2021, Molecular carcinogenesis.

[4]  S. Pothula,et al.  The Role of Chaperone-Mediated Autophagy in Bortezomib Resistant Multiple Myeloma , 2021, Cells.

[5]  Guangji Wang,et al.  Impact of therapy on cancer metabolism in high‐risk localized prostate cancer treated with neoadjuvant docetaxel and androgen deprivation therapy , 2021, The Prostate.

[6]  P. Sorensen,et al.  Androgen receptor (AR) antagonism triggers acute succinate‐mediated adaptive responses to reactivate AR signaling , 2021, EMBO molecular medicine.

[7]  Nadezhda T. Doncheva,et al.  The STRING database in 2021: customizable protein–protein networks, and functional characterization of user-uploaded gene/measurement sets , 2020, Nucleic Acids Res..

[8]  Jianping Ding,et al.  Structure and allosteric regulation of human NAD-dependent isocitrate dehydrogenase , 2020, Cell discovery.

[9]  Jianping Ding,et al.  Structure and allosteric regulation of human NAD-dependent isocitrate dehydrogenase , 2020, Cell Discovery.

[10]  Sanjay Gupta,et al.  Metabolic Reprogramming and Predominance of Solute Carrier Genes during Acquired Enzalutamide Resistance in Prostate Cancer , 2020, Cells.

[11]  G. Scagliotti,et al.  Interactions between androgen receptor signaling and other molecular pathways in prostate cancer progression: Current and future clinical implications. , 2020, Critical reviews in oncology/hematology.

[12]  G. Robert,et al.  Chaperone-Mediated Autophagy and Its Emerging Role in Hematological Malignancies , 2019, Cells.

[13]  I. Mills,et al.  Drivers of AR indifferent anti-androgen resistance in prostate cancer cells , 2019, Scientific Reports.

[14]  Barry Demchak,et al.  Cytoscape Automation: empowering workflow-based network analysis , 2019, Genome Biology.

[15]  A. Cuervo,et al.  Proteome-wide analysis of chaperone-mediated autophagy targeting motifs , 2019, PLoS biology.

[16]  Alireza Hadj Khodabakhshi,et al.  Metascape provides a biologist-oriented resource for the analysis of systems-level datasets , 2019, Nature Communications.

[17]  Peter Vaupel,et al.  The Warburg effect: essential part of metabolic reprogramming and central contributor to cancer progression , 2019, International journal of radiation biology.

[18]  A. Ouchida,et al.  Targetome analysis of chaperone-mediated autophagy in cancer cells , 2019, Autophagy.

[19]  L. Quarles,et al.  Human GPRC6A Mediates Testosterone-Induced Mitogen-Activated Protein Kinases and mTORC1 Signaling in Prostate Cancer Cells , 2019, Molecular Pharmacology.

[20]  M. Loda,et al.  The Metabolic Landscape of Prostate Cancer. , 2019, European urology oncology.

[21]  Christopher S. Hughes,et al.  Single-pot, solid-phase-enhanced sample preparation for proteomics experiments , 2018, Nature Protocols.

[22]  S. Srihari,et al.  Metabolic deregulation in prostate cancer , 2018, bioRxiv.

[23]  Joshua M. Stuart,et al.  Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer , 2018, Cell.

[24]  A. Cuervo,et al.  The coming of age of chaperone-mediated autophagy , 2018, Nature Reviews Molecular Cell Biology.

[25]  Wenming Li,et al.  Signaling and induction of chaperone-mediated autophagy by the endoplasmic reticulum under stress conditions , 2018, Autophagy.

[26]  Xin Lu,et al.  Metabolomics and transcriptomics profiles reveal the dysregulation of the tricarboxylic acid cycle and related mechanisms in prostate cancer , 2018, International journal of cancer.

[27]  M. Nykter,et al.  Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer. , 2018, Cancer discovery.

[28]  S. Catarino,et al.  Molecular control of chaperone-mediated autophagy. , 2017, Essays in biochemistry.

[29]  W. Du,et al.  Rb‐independent E2F3 promotes cell proliferation and alters expression of genes involved in metabolism and inflammation , 2017, FEBS open bio.

[30]  E. Arias.  Methods to Study Chaperone-Mediated Autophagy. , 2017, Methods in enzymology.

[31]  A. Cuervo,et al.  Role of chaperone‐mediated autophagy in metabolism , 2016, The FEBS journal.

[32]  T. Roberts,et al.  Predicting the response of multiple myeloma to the proteasome inhibitor Bortezomib by evaluation of the unfolded protein response , 2016, Blood Cancer Journal.

[33]  M. Gleave,et al.  Clusterin knockdown sensitizes prostate cancer cells to taxane by modulating mitosis , 2016, EMBO molecular medicine.

[34]  F. Saad,et al.  Treatment of mCRPC in the AR-axis-targeted therapy-resistant state. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[35]  J. Yates,et al.  Degradation of HK2 by chaperone-mediated autophagy promotes metabolic catastrophe and cell death , 2015, The Journal of cell biology.

[36]  M. Gleave,et al.  Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies. , 2015, European urology.

[37]  Y. Suh,et al.  Regulated Degradation of Chk1 by chaperone-mediated autophagy in response to DNA damage , 2015, Nature Communications.

[38]  P. Sorensen,et al.  Clusterin facilitates stress-induced lipidation of LC3 and autophagosome biogenesis to enhance cancer cell survival , 2014, Nature Communications.

[39]  Y. Suh,et al.  Deficient chaperone-mediated autophagy in liver leads to metabolic dysregulation. , 2014, Cell metabolism.

[40]  Stefan J. Barfeld,et al.  Androgen-regulated metabolism and biosynthesis in prostate cancer. , 2014, Endocrine-related cancer.

[41]  A. Hsieh,et al.  PI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance , 2014, Asian journal of andrology.

[42]  Andreas Krämer,et al.  Causal analysis approaches in Ingenuity Pathway Analysis , 2013, Bioinform..

[43]  Z. Culig,et al.  Androgen receptor signaling in prostate cancer , 2014, Cancer and Metastasis Reviews.

[44]  G. Kroemer,et al.  Chaperone-mediated autophagy degrades mutant p53. , 2013, Genes & development.

[45]  M. Gleave,et al.  Hsp27 regulates epithelial mesenchymal transition, metastasis, and circulating tumor cells in prostate cancer. , 2013, Cancer research.

[46]  M. Gleave,et al.  A Novel Antiandrogen, Compound 30, Suppresses Castration-Resistant and MDV3100-Resistant Prostate Cancer Growth In Vitro and In Vivo , 2013, Molecular Cancer Therapeutics.

[47]  D. Amadori,et al.  Perspectives on mTOR inhibitors for castration-refractory prostate cancer. , 2012, Current cancer drug targets.

[48]  Kurt Miller,et al.  Increased survival with enzalutamide in prostate cancer after chemotherapy. , 2012, The New England journal of medicine.

[49]  T. Saha.  LAMP2A overexpression in breast tumors promotes cancer cell survival via chaperone-mediated autophagy , 2012, Autophagy.

[50]  A. Cuervo,et al.  Chaperone-mediated autophagy: a unique way to enter the lysosome world. , 2012, Trends in cell biology.

[51]  A. Cuervo,et al.  Chaperone-Mediated Autophagy Is Required for Tumor Growth , 2011, Science Translational Medicine.

[52]  Johan Auwerx,et al.  E2F transcription factor-1 regulates oxidative metabolism , 2011, Nature Cell Biology.

[53]  V. Verkhusha,et al.  A photoconvertible fluorescent reporter to track chaperone-mediated autophagy , 2011, Nature communications.

[54]  I. Mills,et al.  The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis , 2011, The EMBO journal.

[55]  A. Cuervo,et al.  Chaperone-mediated autophagy at a glance , 2011, Journal of Cell Science.

[56]  Wenming Li,et al.  Chaperone-mediated autophagy: machinery, regulation and biological consequences , 2011, Cellular and Molecular Life Sciences.

[57]  M. Gleave,et al.  Hsp27 promotes insulin-like growth factor-I survival signaling in prostate cancer via p90Rsk-dependent phosphorylation and inactivation of BAD. , 2010, Cancer research.

[58]  M. Gleave,et al.  Cooperative interactions between androgen receptor (AR) and heat-shock protein 27 facilitate AR transcriptional activity. , 2007, Cancer research.

[59]  M. Gleave,et al.  Small interference RNA targeting heat‐shock protein 27 inhibits the growth of prostatic cell lines and induces apoptosis via caspase‐3 activation in vitro , 2006, BJU international.

[60]  A. Cuervo,et al.  Autophagy as a cell-repair mechanism: activation of chaperone-mediated autophagy during oxidative stress. , 2006, Molecular aspects of medicine.

[61]  M. Gleave,et al.  Increased Hsp27 after androgen ablation facilitates androgen-independent progression in prostate cancer via signal transducers and activators of transcription 3-mediated suppression of apoptosis. , 2005, Cancer research.

[62]  T. Pawson,et al.  Protein phosphorylation in signaling--50 years and counting. , 2005, Trends in biochemical sciences.

[63]  David J. Kwiatkowski,et al.  Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[64]  J. Blenis,et al.  Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. , 2002, Genes & development.

[65]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[66]  M. Gleave,et al.  Synergistic chemosensitization and inhibition of progression to androgen independence by antisense Bcl‐2 oligodeoxynucleotide and paclitaxel in the LNCaP prostate tumor model , 2001, International journal of cancer.

[67]  Overton Wr,et al.  Modified histogram subtraction technique for analysis of flow cytometry data , 1988 .

[68]  W R Overton,et al.  Modified histogram subtraction technique for analysis of flow cytometry data. , 1988, Cytometry.